Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 2, 2007

View Archived Issues

Hana Biosciences presents new data on compounds utilizing its Optisome technology

Medivir presents third quarter 2007 results

Recent patents describe novel agents for anxiety, psychosis and sleep disorders

New antiglaucoma agents reported in recent Allergan patent

Recent Ranbaxy patent discloses new therapeutic agents for urinary incontinence

CAM-24 shows antipsychotic activity in vivo with low potential for motor side effects

SNAP25 may be a common susceptibility gene for ADHD and early-onset bipolar affective disorder

European Commission grants marketing authorization for Nexavar

The Hsp90 inhibitor NVP-AUY-922 profiled at the AACR-NCI-EORTC meeting

Epix reports positive results from phase IIb clinical trial of PRX-07034 in obesity

Peptech successfully completes phase I trial for PN-0621

Results of BEYOND study in Betaferon do not support regulatory filing for 500 mcg dose

Pharming completes randomized treatments in clinical trial of Rhucin

TST-10088 well tolerated in ongoing phase I study

Favorable results seen in phase I study of XMT-1001

Threshold updates corporate activities and clinical development

Relypsa formed as a spin-out company of Amgen and Ilypsa

Battelle acquires the assets of Ventaira Pharmaceuticals

Eli Lilly and Glenmark enter license agreement for GRC-6211

Adherex initiates collaborative phase III trial of sodium thiosulfate

Forbes Medi-Tech close to compound selection in FM-TP2000 and FM-TP3000 series

Sciele and Plethora initiate patient enrollment in phase III trials of PSD-502

Nycomed to acquire Bradley Pharmaceuticals

Inovio and Tripep begin enrollment of patients for phase I/II clinical trial of ChronVac-C

Bayer HealthCare submits rivaroxaban MAA to the EMEA

Meda submits NDA for BEMA Fentanyl to FDA

FDA approves Allergan's Combigan for reduction of intraocular pressure

Results from phase III registration trial of satraplatin fail to achieve statistical significance

U.K. grants marketing authorization to Javelin's Dyloject for acute pain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 23, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
Psychedelic space expanding on Trump’s EO
BioWorld
Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...